225 related articles for article (PubMed ID: 32460028)
1. Expression of RUNX1-ETO Rapidly Alters the Chromatin Landscape and Growth of Early Human Myeloid Precursor Cells.
Nafria M; Keane P; Ng ES; Stanley EG; Elefanty AG; Bonifer C
Cell Rep; 2020 May; 31(8):107691. PubMed ID: 32460028
[TBL] [Abstract][Full Text] [Related]
2. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding.
Ptasinska A; Assi SA; Mannari D; James SR; Williamson D; Dunne J; Hoogenkamp M; Wu M; Care M; McNeill H; Cauchy P; Cullen M; Tooze RM; Tenen DG; Young BD; Cockerill PN; Westhead DR; Heidenreich O; Bonifer C
Leukemia; 2012 Aug; 26(8):1829-41. PubMed ID: 22343733
[TBL] [Abstract][Full Text] [Related]
3. RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.
Loke J; Assi SA; Imperato MR; Ptasinska A; Cauchy P; Grabovska Y; Soria NM; Raghavan M; Delwel HR; Cockerill PN; Heidenreich O; Bonifer C
Cell Rep; 2017 May; 19(8):1654-1668. PubMed ID: 28538183
[TBL] [Abstract][Full Text] [Related]
4. RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.
Ptasinska A; Pickin A; Assi SA; Chin PS; Ames L; Avellino R; Gröschel S; Delwel R; Cockerill PN; Osborne CS; Bonifer C
Cell Rep; 2019 Sep; 28(12):3022-3031.e7. PubMed ID: 31533028
[TBL] [Abstract][Full Text] [Related]
5. RUNX1/ETO and mutant KIT both contribute to programming the transcriptional and chromatin landscape in t(8;21) acute myeloid leukemia.
Chin PS; Assi SA; Ptasinska A; Imperato MR; Cockerill PN; Bonifer C
Exp Hematol; 2020 Dec; 92():62-74. PubMed ID: 33152396
[TBL] [Abstract][Full Text] [Related]
6. t(8;21) Acute Myeloid Leukemia as a Paradigm for the Understanding of Leukemogenesis at the Level of Gene Regulation and Chromatin Programming.
Kellaway S; Chin PS; Barneh F; Bonifer C; Heidenreich O
Cells; 2020 Dec; 9(12):. PubMed ID: 33322186
[TBL] [Abstract][Full Text] [Related]
7. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.
Nishida S; Hosen N; Shirakata T; Kanato K; Yanagihara M; Nakatsuka S; Hoshida Y; Nakazawa T; Harada Y; Tatsumi N; Tsuboi A; Kawakami M; Oka Y; Oji Y; Aozasa K; Kawase I; Sugiyama H
Blood; 2006 Apr; 107(8):3303-12. PubMed ID: 16380455
[TBL] [Abstract][Full Text] [Related]
8. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia.
Dunne J; Gascoyne DM; Lister TA; Brady HJ; Heidenreich O; Young BD
Cancer Res; 2010 May; 70(10):3985-95. PubMed ID: 20460523
[TBL] [Abstract][Full Text] [Related]
9. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
10. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
[TBL] [Abstract][Full Text] [Related]
11. Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network.
Zaidi SK; Dowdy CR; van Wijnen AJ; Lian JB; Raza A; Stein JL; Croce CM; Stein GS
Cancer Res; 2009 Nov; 69(21):8249-55. PubMed ID: 19826043
[TBL] [Abstract][Full Text] [Related]
12. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.
Nick HJ; Kim HG; Chang CW; Harris KW; Reddy V; Klug CA
Blood; 2012 Feb; 119(6):1522-31. PubMed ID: 21937700
[TBL] [Abstract][Full Text] [Related]
13. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
Bakshi R; Zaidi SK; Pande S; Hassan MQ; Young DW; Montecino M; Lian JB; van Wijnen AJ; Stein JL; Stein GS
J Cell Sci; 2008 Dec; 121(Pt 23):3981-90. PubMed ID: 19001502
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of RUNX3 inhibits normal human myeloid development.
Menezes AC; Jones R; Shrestha A; Nicholson R; Leckenby A; Azevedo A; Davies S; Baker S; Gilkes AF; Darley RL; Tonks A
Leukemia; 2022 Jul; 36(7):1769-1780. PubMed ID: 35490198
[TBL] [Abstract][Full Text] [Related]
15. The acute myeloid leukemia associated AML1-ETO fusion protein alters the transcriptome and cellular progression in a single-oncogene expressing in vitro induced pluripotent stem cell based granulocyte differentiation model.
Tijchon E; Yi G; Mandoli A; Smits JGA; Ferrari F; Heuts BMH; Wijnen F; Kim B; Janssen-Megens EM; Schuringa JJ; Martens JHA
PLoS One; 2019; 14(12):e0226435. PubMed ID: 31869378
[TBL] [Abstract][Full Text] [Related]
16. A RUNX1/ETO-SKP2-CDKN1B axis regulates expression of telomerase in t (8;21) acute myeloid leukemia.
Moses EJ; Azlan A; Khor KZ; Mot YY; Mohamed S; Seeni A; Barneh F; Heidenreich O; Yusoff N
Cell Mol Life Sci; 2023 Feb; 80(3):70. PubMed ID: 36820913
[TBL] [Abstract][Full Text] [Related]
17. Identification of a dynamic core transcriptional network in t(8;21) AML that regulates differentiation block and self-renewal.
Ptasinska A; Assi SA; Martinez-Soria N; Imperato MR; Piper J; Cauchy P; Pickin A; James SR; Hoogenkamp M; Williamson D; Wu M; Tenen DG; Ott S; Westhead DR; Cockerill PN; Heidenreich O; Bonifer C
Cell Rep; 2014 Sep; 8(6):1974-1988. PubMed ID: 25242324
[TBL] [Abstract][Full Text] [Related]
18. RUNX1 inhibits proliferation and induces apoptosis of t(8;21) leukemia cells
Liu S; Xing Y; Lu W; Li S; Tian Z; Xing H; Tang K; Xu Y; Rao Q; Wang M; Wang J
Haematologica; 2019 Aug; 104(8):1597-1607. PubMed ID: 30792202
[TBL] [Abstract][Full Text] [Related]
19. Chromatin modifications induced by the AML1-ETO fusion protein reversibly silence its genomic targets through AML1 and Sp1 binding motifs.
Maiques-Diaz A; Chou FS; Wunderlich M; Gómez-López G; Jacinto FV; Rodriguez-Perales S; Larrayoz MJ; Calasanz MJ; Mulloy JC; Cigudosa JC; Alvarez S
Leukemia; 2012 Jun; 26(6):1329-37. PubMed ID: 22289984
[TBL] [Abstract][Full Text] [Related]
20. Definition of a small core transcriptional circuit regulated by AML1-ETO.
Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
